NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NT-112 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NT-112 overview

NT-112 is under development for the treatment of advanced solid tumors including metastatic non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer. The therapeutic candidate comprises autologous T-cells genetically engineered to express HLA-C*08:02-restricted T cell receptor (TCR) targeting cells expressing KRAS G12D. It is administered through parenteral route.

Neogene Therapeutics overview

Neogene Therapeutics, Inc (Neogene Therapeutics), a subsidiary of Neogene Therapeutics BV, operates as pre-clinical stage biotechnology company. Neogene Therapeutics is headquartered in Santa Monica, California, the US.

For a complete picture of NT-112’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.